Drug Trial Radar · NCT01838395
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Apr 2013
Primary completion
Mar 2016
Study completion Jul 20, 2023
Sponsor
- Lead sponsor
- BioLineRx, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study is designed to assess if BL-8040 in combination with cytarabine (Ara-C) can help controlling the disease in patients with Acute Myeloid Leukemia (AML) that have relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied.
Conditions
- Acute Myeloid Leukemia
Interventions
Ara-CDrug
IV (intravenous administration)
BL-8040Drug
SC (subcutaneous injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Participants were followed for the duration of the hospital stay and the follow-up period, an expected average of 6 weeks.
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Jacksonville, Florida
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
MD Anderson Cancer Center
Houston, Texas
Rambam Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Meir Medical Center
Kfar Saba, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.